What have we learnt from past failures in Alzheimer’s disease drug discovery?

References

• Cantarero-Prieto D, Leon PL, Blazquez-Fernandez C, et al. The economic cost of dementia: a systematic review. Dementia. 2020;19(8):2637–2657.
   PubMedGoogle Scholar
• Sado M, Ninomiya A, Shikimoto R, et al. The estimated cost of dementia in Japan, the most aged society in the world. PLoS One. 2018;13(11):e0206508.
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. Jama. 2019;322:1589–1599.
   PubMed Web of Science ®Google Scholar
• Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292–323.
   PubMed Web of Science ®Google Scholar
• Masters CL, Bateman R, Blennow K, et al. Alzheimer’s disease. Nat Rev Dis Primers. 2015;1:15056.
   PubMed Web of Science ®Google Scholar
• Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci. 2020;23(10):1183–1193.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos P, Torrellas C, et al. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol. 2014;1175:323–556.
   PubMedGoogle Scholar
• Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer’s Disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genomic Med Pharmacogenomics. 2016;1:151–209.
   Google Scholar
• Cacabelos R, Carril JC, Cacabelos N, et al. Sirtuins in Alzheimer’s disease: SIRT2-related genophenotypes and implications for PharmacoEpiGenetics. Int J Mol Sci. 2019;20:E1249.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Population-level pharmacogenomics for precision drug development in dementia. Exp Rev Precis Med Drug Dev. 2018;3(3):163–188.
   Web of Science ®Google Scholar
• Cacabelos R. Pharmacogenomics of cognitive dysfunction and neuropsychiatric disorders in dementia. Int J Mol Sci. 2020;21(9):3059.
   Web of Science ®Google Scholar
• Tcw J, Goate AM. Genetics of β-amyloid precursor protein in Alzheimer’s disease. Cold Spring Harb Perspect Med. 2017;7(6):a024539.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Exp Rev Clin Pharmacol. 2019;12(5):407–442.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Have there been improvement in Alzheimer’s disease drug discovery over the past 5 years? Exp Opin Drug Discovery. 2018;13(6):523–538.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. How plausible is an Alzheimer’s disease vaccine? Expert Opin Drug Discov. 2020;15(1):1–6.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Goldgaber D, Vostrov A, et al. APOE-TOMM40 in the Pharmacogenomics of demetia. J Pharmacogen Pharmacoprot. 2014;5:135.
   Google Scholar
• Cacabelos R. Pharmacogenomic of drugs to treat brain disorders. Exp Rev Precis Med Drug Dev. 2020;5(3):181–234.
   Web of Science ®Google Scholar
• Cacabelos R, Carril JC, Corzo L, et al. Influence of pathogenic and metabolic genes on the pharmacogenetics of mood disorders in Alzheimer’s disease. Pharmaceuticals. 2021;14:366.
   Web of Science ®Google Scholar
• Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement. 2020;6(1):e12050. *Updating of drug development and clinical trials in AD.
   Web of Science ®Google Scholar
• Lalli G, Schott JM, Hardy J, et al. Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? EMBO Mol Med. 2021;13(8):e14781.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Banerjee D. A primer on the evolution of aducanumab: the first antibody approved for treatment of Alzheimer’s disease. J Alzheimers Dis. 2021;83(4):1537–1552.
   PubMed Web of Science ®Google Scholar
• Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17(4):696–701.
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–56.
   PubMed Web of Science ®Google Scholar
• Ferrero J, Williams L, Stella H, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement. 2016;2(3):169–176.
   Google Scholar
• Tolar M, Abushakra S, Hey JA, et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95.
   PubMed Web of Science ®Google Scholar
• VandeVrede L, Gibbs DM, Koestler M, et al. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement. 2020;12(1):e12101.
   Web of Science ®Google Scholar
• Cacabelos R, Carrera I, Martínez-Iglesias O, et al. What is the gold standard model for Alzheimer’s disease drug discovery and development? Expert Opin Drug Discov. 2021;25:1–26.
   Google Scholar
• Guttenplan KA, Weigel MK, Prakash P, et al. Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature. 2021;599(7883):102–107.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease. Exp Opin Drug Metab Toxicol. 2020;16(8):673–701.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Carril JC, Sanmartín A, et al. Pharmacoepigenetic processors: epigenetic drugs, Drug resistance, Toxicoepigenetics, and nutriepigenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford: Academic Press/Elsevier; 2019. p. 191–424.
   Google Scholar
• Cacabelos R, Cacabelos P, Carril JC. Epigenetics and pharmacoepigenetics of age-related neurodegenerative disorders. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford: Academic Press/Elsevier; 2019. p. 903–950.
   Google Scholar